Newsletter

February 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: February Scorecard Number of Signals 13 Percent Correct – Prev Close to 5-day Peak 85% Avg Increase – Next open to 5-day Peak 12% Other stats: Number of signals over $10/share 7 Number […]

0Comments

InflaRx Announces Positive Initial Data from Phase IIa Clinical Trial

On February 26, InflaRx, N.V. (IFRX) announced positive initial data from the first 5 patients enrolled in its Phase IIa open label clinical trial for IFX-1. Two out of the five patients achieved complete remission of Pyoderma Gangraenosum (PG), a rare and debilitating autoinflammatory skin disease. Although the exact prevalence of PG is unknown, current […]

0Comments

January 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: January Scorecard Number of Signals 18 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 11 Number […]

0Comments

December 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: December Scorecard Number of Signals 19 Percent Correct – Prev Close to 5-day Peak 89% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 11 Number […]

0Comments

November 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: November Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 92% Avg Increase – Next open to 5-day Peak 14% Other stats: Number of signals over $10/share 6 Number […]

0Comments

October 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October Scorecard Number of Signals 20 Percent Correct – Prev Close to 5-day Peak 95% Avg Increase – Next open to 5-day Peak 9% Other stats: Number of signals over $10/share 10 Number […]

0Comments

Akorn Gets FDA Approval for Betamethasone Dipropionate Lotion USP (Augmented), 0.05%

Akorn, Inc. (AKRX) announced on October 14 that the company received FDA approval for betamethasone dipropionate lotion USP (augmented), 0.05%.  Akorn had filed an Abbreviated New Drug Application (ANDA) with the FDA. Betamethasone dipropionate lotion (augmented) is a corticosteroid indicated for the relief of dermatoses in patients 13 years of age and older. U.S. sales […]

0Comments

September 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: September Scorecard Number of Signals 7 Percent Correct – Prev Close to 5-day Peak 71% Avg Increase – Next open to 5-day Peak 5% Other stats: Number of signals over $10/share 3 Number […]

0Comments

August 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: August Scorecard Number of Signals 8 Percent Correct – Prev Close to 5-day Peak 88% Avg Increase – Next open to 5-day Peak 6% Other stats: Number of signals over $10/share 6 Number […]

0Comments

AbbVie Receives FDA Approval for RINVOQ

On August 16, AbbVie (ABBV) announced that it received FDA approval of RINVOQ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor. The drug is expected to be available in the U.S. by the end of August 2019. RINVOQ treats adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate […]

0Comments

Latest of Knowledge Center